RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma
Open Access
- 1 January 2018
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 15 (14) , 1648-1657
Abstract
Pirarubicin (THP) is a new generation cell cycle nonspecific anthracycline anticancer drug. Pirarubicin and pirarubicin-based combination therapies have been demonstrated to be effective against HCC in TACE. However, the drug resistance limits its therapeutic efficacy. Receptor-interacting protein kinase 1 (RIPK1) displays a critical role in cell death. Here we found that RIPK1 and p21 may participate in the resistance to pirarubicin. In this study, we first found that inhibition of RIPK1 significantly decreased pAKT and increased p21, accompanied by G0/G1 phase cell cycle arrest and cell anti-proliferation in pirarubicin-treated hepatocellular carcinoma cells. Moreover, phosphorylation of AKT reversed the anti-proliferative effect of RIPK1 inhibitor in HCC, which proved that RIPK1-AKT-P21-dependent pathway played a key role in pirarubicin resistance. Using a mouse xenograft model, we further found that RIPK1 inhibitor combined with pirarubicin exerted synergistic anti-tumor effect in vivo. Upon exposure to pirarubicin treatment, xenografts under RIPK1 inhibition maintained higher levels of p21 than control xenografts. In conclusion, the results in our study demonstrated that RIPK1 inhibition enhances the anti-tumor effect of pirarubicin by overcoming drug resistance. RIPK1 inhibitor might be used as an adjuvant to potentiate the inhibitory effect of pirarubicin against primary hepatocellular carcinoma.Keywords
This publication has 33 references indexed in Scilit:
- Structural Basis of RIP1 Inhibition by NecrostatinsStructure, 2013
- RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF-κB–Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTENCancer Research, 2009
- Identification of RIP1 kinase as a specific cellular target of necrostatinsNature Chemical Biology, 2008
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsDrug Resistance Updates, 2008
- p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradationOncogene, 2007
- Requirement for p53 and p21 to Sustain G 2 Arrest After DNA DamageScience, 1998
- Inhibition of cyclin-dependent kinases by p21.Molecular Biology of the Cell, 1995
- Separate domains of p21 involved in the inhibition of Cdk kinase and PCNANature, 1995
- Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastasesEuropean Journal of Cancer, 1994
- The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinasesCell, 1993